Related Experiment Videos
Indobufen in secondary prevention of transient ischaemic attack. Multicentre Ischaemic Attack Study Group
1Medical Department, Farmitalia Carlo Erba ROSCA, Vienna, Austria.
Insights
Indobufen significantly reduced transient ischaemic attacks (TIAs) in patients over 12 months. The drug demonstrated good efficacy and safety, with most side effects being mild and transient.
Area of Science:
- Neurology
- Pharmacology
Background:
- Transient ischaemic attacks (TIAs) are critical warning signs for future cerebrovascular events.
- Effective secondary prevention strategies are crucial to reduce stroke risk.
Purpose of the Study:
- To evaluate the efficacy and safety of indobufen for the secondary prevention of TIAs.
- To assess the long-term effects of indobufen treatment on TIA recurrence.
Main Methods:
- A 12-month, open-label study involving 270 patients with a history of TIAs.
- Patients received oral indobufen 100 mg twice daily.
- Data on TIA incidence, side effects, and clinical outcomes were collected.
Main Results:
- Indobufen significantly reduced the average number and incidence of TIAs by over 0.001 after one month, with sustained suppression throughout treatment.
- Most adverse events were mild and transient, primarily occurring within the first month.
- Treatment was discontinued in 17 patients due to side effects, fatal events, or protocol non-compliance.
Conclusions:
- Indobufen is effective in the secondary prevention of TIAs.
- The drug exhibits a favorable safety profile, with manageable side effects.
- Both patients and physicians reported good overall efficacy and tolerability of indobufen.
Abstract:
The secondary prevention of transient ischaemic attacks was assessed in 270 patients treated orally with 100 mg indobufen given twice daily for 12 months. After 1 month's treatment, the average number and average incidence of transient ischaemic attacks were reduced significantly (P less than 0.001) and remained suppressed throughout the treatment period. Treatment was interrupted in 17 patients: in two because of side-effects (gastric disturbances); in 10 because of fatal events (six completed strokes, two myocardial infarcts and two unrelated deaths); and in five due to poor protocol compliance. Progression to reversible ischaemic neurological deficit occurred in five patients. Most side-effects were mild and transient, mainly occurring in the first month of treatment. Overall, indobufen was judged to have good efficacy and safety by both patients and physicians.